Results 21 to 30 of about 5,445 (182)
ESC Heart Failure, 2021 Aims Real‐world data on the use of tolvaptan, an oral selective vasopressin 2 receptor antagonist, for patients with heart failure (HF) are not available in Western countries because tolvaptan is not indicated in the Western countries for volume overload
Takashi Kuragaichi, Yukihito Sato
doaj +1 more source
Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan
Scientific Reports, 2021 Within no definite diuretic protocol for acute heart failure (AHF) patients and its variation in regional clinical guidelines, the latest national guidelines in Japan commends use of tolvaptan in diuretic-resistant patients.
Yusuke Yamazaki +6 more
doaj +1 more source
Tolvaptan response predictors in acute heart failure patients with congestion [PDF]
Pharmaceutical Sciences Asia, 2022 Tolvaptan has been used in many countries as an adjunct to diuretic therapy for heart failure. The identification of predictors of response to tolvaptan is essential in developing individual treatment plans, and this study therefore aims to identify ...
Hindun Wilda Risni +2 more
doaj +1 more source
Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure [PDF]
, 2015 2015-08Although reports suggest that tolvaptan does not reduce survival or subsequent hospitalization rates in heart failure patients, its continuous use has shown good outcomes in some patients who cannot be effectively managed with high doses of loop ...
Ishii, Hideki +9 more
core +1 more source
Nefrología (English Edition), 2023 Background: The irreversible progression of autosomal dominant polycystic kidney disease (ADPKD) to end-stage renal disease (ESRD) is delayed by tolvaptan.
Xuanwei Li +4 more
doaj +3 more sources
Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
Kidney Diseases, 2021 Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, accounting for approximately 5% of all ESRD cases worldwide.
Fei Liu +4 more
doaj +1 more source
The baseline demographic and laboratory data of the tolvaptan group and non-tolvaptan group.
, 2022 The baseline demographic and laboratory data of the tolvaptan group and non-tolvaptan group.
Akinari Sekine (4357189) +8 more
core +1 more source
Patient Preference and Adherence, 2021 Holger Schirutschke, Peter Gross, Alexander Paliege, Christian Hugo University Hospital Carl Gustav Carus at the Technische, Universität Dresden, Department of Internal Medicine III, Division of Nephrology, Dresden, GermanyCorrespondence: Holger ...
Schirutschke H +3 more
doaj
Effectiveness of Tolvaptan Treatment in Hyponatremic Patients
Turkish Journal of Internal Medicine, 2020 Objective: Non-peptide vasopressin receptor antagonists (vaptans) are effective at increasing sodium in euvolemic and hypervolemic states and appear safe. We aimed to evaluate the efficacy of tolvaptan in euvolemic or hypervolemic hyponatremic patients.
Mehmet Fethullah Aydın +4 more
doaj +1 more source
European Journal of Histochemistry, 2022 Heart failure (HF) is often complicated by renal dysfunction. Tolvaptan and valsartan are two well-known agents for the treatment of HF. However, the role of tolvaptan/valsartan combination on HF with renal dysfunction remains unclear.
Fengqin Yan +4 more
doaj +1 more source